| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OKUR | Common Stock | Other | +346K | 346K | Oct 7, 2024 | Holdings of BML Investment Partners, L.P. | F1, F2 | |||
| transaction | OKUR | Common Stock | Other | +102K | 102K | Oct 7, 2024 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Received in exchange for 3,457,395 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure"). |
| F2 | BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| F3 | Received in exchange for 1,020,769 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure"). |